Clinical trials are ongoing for the first long-lasting, reversible male birth control which is the first innovation in male birth control since the vasectomy hit the scene in 1897. This week’s Found guest is Kevin Eisenfrats, the co-founder and CEO of Contraline () , a biotech company developing innovative methods to use hydrogel as a contraceptive. Contraline’s first product, ADAM, is what some are calling the first male IUD. The company will begin clinical trials in the U.S. very soon.
In this conversation they cover:
• The process of fundraising when you’re creating a completely new category
• Why the overturning of Roe V. Wade has led to increased interest in ADAM by men in the US
• The future of Contraline and other innovations that use hydrogels
(0:00) Introduction
(2:26) The challenges to male birth control
(6:53) Why hydrogel works
(9:35) Developing ADAM
(15:08) Cultural reaction to ADAM
(20:18) Entrepreneurship in medicine
(22:39) FDA approval process
(28:09) What’s next for Contraline
(34:23) Host conversation
Found posts every Tuesday. Subscribe on Apple () , Spotify () or wherever you listen to podcasts () to be alerted when new episodes drop. Check out the other TechCrunch podcast: Equity () .
Connect with us:
• On Twitter ()
• On Instagram ()
• Via email: found@techcrunch.com
